Patents Assigned to GlaxoSmithKline LLC
  • PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USES
    Publication number: 20120315291
    Abstract: The present invention relates to compounds of formula (I): wherein; R1 represents hydrogen or C1-3alkyl; n is an integer having a value of 1 to 5; X represents O or NH; Y represents C or N; or a pharmaceutically acceptable salt thereof, have been shown to be inducers of human interferon and may possess an improved profile with respect to known inducers of human interferon, for example enhanced potency. The compounds of the invention may therefore be useful in the treatment of various disorders, in particular the treatment of infectious diseases, cancer, allergic diseases and other inflammatory conditions, and their use as vaccine adjuvants.
    Type: Application
    Filed: February 8, 2011
    Publication date: December 13, 2012
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: Helene Bazin-Lee, Diane Mary Coe, David A. Johnson, Charlotte Jane Mitchell
  • NOVEL USES
    Publication number: 20120315267
    Abstract: The present invention relates to antibodies which multiple antigen specificities and their use in treating human diseases
    Type: Application
    Filed: February 9, 2011
    Publication date: December 13, 2012
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: Stephanie Jane Clegg, Eric Dobrzynski, Jonathan Henry Ellis, Volker Germaschewski, Alexis Paul Godillot, Zdenka Ludmila Jonak, Alan Peter Lewis, John Richard White
  • 6-AMINO-2--9-[5-(1-PIPERIDINYL)-7,9-DIHYDRO-8H-PURIN-8-ONE MALEATE
    Publication number: 20120308609
    Abstract: The present invention relates to a compound which is 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one: in the form of a maleate salt, may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Application
    Filed: February 8, 2011
    Publication date: December 6, 2012
    Applicant: GlaxoSmithKline LLC
    Inventors: Robert Hermann Gibbon, Amanda Lucas, Stephen Andrew Hermitage
  • Prolyl hydroxylase inhibitors
    Patent number: 8324208
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: December 4, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Kevin J. Duffy, Duke M. Fitch, Jian Jin, Ronggang Liu, Antony N. Shaw, Kenneth Wiggall
  • Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide
    Patent number: 8314232
    Abstract: The present invention relates to a process of preparing a compound of the following formula III: wherein R1-R4 are as defined herein. The present invention also relates to the preparation of intermediates used to prepare the compound of formula III.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: November 20, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Nicole Marie Deschamps, Michael Tolar Martin, Michael John Monteith, Xiaoming Zhou
  • COMPOUNDS
    Publication number: 20120283438
    Abstract: The present invention includes novel compounds useful in the treatment of various disorders in particular infectious diseases, cancer, and allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, and as vaccine adjuvants.
    Type: Application
    Filed: July 18, 2012
    Publication date: November 8, 2012
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: Linos LAZARIDES, Stephen Allan SMITH, Richard STOCKER, Colin Jack THEOBALD
  • Chemical compounds
    Patent number: 8304419
    Abstract: The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: November 6, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Pek Yoke Chong, Andrew James Peat, Paul Richard Sebahar, Michael Youngman, Huichang Zhang
  • Coating for Latex Articles
    Publication number: 20120240937
    Abstract: This invention relates to novel articles, particularly latex barrier articles, being coated with an antimicrobial coating useful to reduce the risk of cross-contamination and/or infection by harmful pathogenic microorganisms.
    Type: Application
    Filed: December 9, 2010
    Publication date: September 27, 2012
    Applicant: GlaxoSmithKline LLC
    Inventors: William Bess, Leonard Mackles
  • COMBINATION
    Publication number: 20120245180
    Abstract: The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a novel combination comprising the MEK inhibitor: N-{3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and the PI3 kinase inhibitor: 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same, and methods of using such combinations in the treatment of cancer.
    Type: Application
    Filed: September 28, 2010
    Publication date: September 27, 2012
    Applicant: GlaxoSmithKline LLC
    Inventors: Kurt R. Auger, Kurtis Earl Bachman, Tona M. Gilmer, James G. Greger, JR., Joel David Greshock, Sylvie Laquerre, Li Liu, Shannon Renae Morris
  • Inhibitors of Akt activity
    Patent number: 8273782
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: September 25, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding
  • Compounds
    Patent number: 8268839
    Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: September 18, 2012
    Assignee: Glaxosmithkline LLC
    Inventors: Ivan Leo Pinto, Shahzad Sharooq Rahman, Neville Hubert Nicholson
  • Nicotinamide derivatives useful as P38 inhibitors
    Patent number: 8252818
    Abstract: Compounds of formula (I): are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: August 28, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Nicola Mary Aston, Paul Bamborough, Ann Louise Walker
  • COMBINATION
    Publication number: 20120202835
    Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof.
    Type: Application
    Filed: October 8, 2010
    Publication date: August 9, 2012
    Applicant: GlaxoSmithKline LLC
    Inventors: Melissa Dumble, Tona Gilmer, Rakesh Kumar, Peter F. Lebowitz, Shannon Renae Morris, Sylvie Laquerre
  • Processes for preparing benzimidazole thiophenes
    Patent number: 8236954
    Abstract: A process for preparing benzimidazole thiophenes including 5-{6-[(4-methylpiperazin-1-yl)methyl]-1H-benzimidazol-1-yl}-3-{(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy}thiophene-2-carboxamide.
    Type: Grant
    Filed: June 23, 2008
    Date of Patent: August 7, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Amanda Caroline Lucas, Robert M. Harris, Christopher James Nichols, Andrew Jonathan Whitehead
  • COMBINATION
    Publication number: 20120196886
    Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof.
    Type: Application
    Filed: October 8, 2010
    Publication date: August 2, 2012
    Applicant: Glaxosmithkline LLC
    Inventors: Melissa Dumble, Tona Gilmer, Rakesh Kumar, Peter F. Lebowitz, Shannon Renae Morris, Sylvie Laquerre
  • Peptides and compounds that bind to a receptor
    Patent number: 8227422
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: July 24, 2012
    Assignee: Glaxosmithkline LLC
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, David J. Duffin, Christian M. Gates, Sherril S. Haselden, Larry C. Mattheakis, Peter J. Schatz, Christopher R. Wagstrom, Nicholas C. Wrighton
  • Chemical compounds
    Patent number: 8222261
    Abstract: The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: July 17, 2012
    Assignee: GlaxoSmithKline, LLC
    Inventors: Subba R Katamreddy, Richard Dama Caldwell, Dennis Heyer, Vincente Samano, James Benjamin Thompson, Andrew J Carpenter, Christopher R Conlee, Eric Eugene Boros, Brian D Thompson
  • Orphan nuclear receptor
    Patent number: 8221991
    Abstract: The present invention relates to a novel human orphan nuclear receptor that binds to a cytochrome P-450 monooxygenase (CYP) promoter and that is activated by compounds that induce CYP gene expression. The invention further relates to nucleic acid sequences encoding such a receptor, to methods of making the receptor and to methods of using the receptor and nucleic acid sequences encoding same. The invention also relates to non-human animals transformed to express the human receptor and to methods of using such animals to screen compounds for drug interactions and toxicities.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: July 17, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Steven A. Kliewer, Stacey A. Jones, Timothy M. Willson
  • Nasal dilator
    Patent number: D672461
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: December 11, 2012
    Assignee: GlaxoSmithKline, LLC
    Inventors: Kyle N Brogden, Gustav R Fenton, Snigdha Mishra
  • Nasal dilator
    Patent number: D672872
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: December 18, 2012
    Assignee: GlaxoSmithKline, LLC
    Inventors: Jeffrey S. Brunner, Gustav R Fenton, Snigdha Mishra